605653-52-9

Basic information

• Product Name: tert-butyl ((2S,3R)-4-((4-formyl-N-isobutylphenyl)sulfonamido)-3-hydroxy-1-phenylbutan-2-yl)carbamate
• Synonyms: tert-butyl ((2S,3R)-4-((4-formyl-N-isobutylphenyl)sulfonamido)-3-hydroxy-1-phenylbutan-2-yl)carbamate
• CAS NO: 605653-52-9
• Molecular Weight: 504.648
• Mol File: 605653-52-9.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: tert-butyl ((2S,3R)-4-((4-formyl-N-isobutylphenyl)sulfonamido)-3-hydroxy-1-phenylbutan-2-yl)carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl ((2S,3R)-4-((4-formyl-N-isobutylphenyl)sulfonamido)-3-hydroxy-1-phenylbutan-2-yl)carbamate(605653-52-9)
• EPA Substance Registry System: tert-butyl ((2S,3R)-4-((4-formyl-N-isobutylphenyl)sulfonamido)-3-hydroxy-1-phenylbutan-2-yl)carbamate(605653-52-9)

Safety Data

• Hazardous Substances Data: 605653-52-9(Hazardous Substances Data)

Upstream product

• 85822-16-8 4-formylbenzene-1-sulfonyl chloride 
• 160232-08-6 (2R,3S)-3-tert-butoxycarbonylamino-1-isobutylamino-4-phenyl-2-butanol 
• 854739-70-1 tert-butyl ((2S,3R)-3-hydroxy-4-(N-isobutyl-4-vinylphenylsulfonamido)-1-phenylbutan-2-yl)carbamate 
• 98-59-9 p-toluenesulfonyl chloride 
• 69232-47-9 (4-(chlorosulfonyl)phenyl)methylene diacetate 
• 98760-08-8 (1-oxiranyl-2-phenylethyl)carbamic acid tert-butyl ester 
• 854745-35-0 (acetyloxy)(4-{[{(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-4-phenylbutyl}(isobutyl)amino]sulfonyl}phenyl)methyl Acetate 

Downstream Products

• 910909-96-5 C₂₆H₃₈N₂O₆S 
• 854739-71-2 ((1S,2R)-1-benzyl-2-hydroxy-3-{[4-(hydroxyiminomethyl)benzenesulfonyl](isobutyl)amino}propyl)carbamic acid tert-butyl ester 
• 1037666-14-0 C₂₁H₃₀N₂O₄S 

Relevant articles and documents

Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance

Structure-based design and synthesis of novel HIV protease inhibitors are described. The inhibitors are designed specifically to interact with the backbone of HIV protease active site to combat drug resistance. Inhibitor 3 has exhibited exceedingly potent enzyme inhibitory and antiviral potency. Furthermore, this inhibitor maintains impressive potency against a wide spectrum of HIV including a variety of multi-PI-resistant clinical strains. The inhibitors incorporated a stereochemically defined 5-hexahydrocyclopenta[b] furanyl urethane as the P2-ligand into the (R)-(hydroxyethylamino)sulfonamide isostere. Optically active (3aS,5R,6aR)-5-hydroxy-hexahydrocyclopenta[e]furan was prepared by an enzymatic asymmetrization of meso-diacetate with acetyl cholinesterase, radical cyclization, and Lewis acid-catalyzed anomeric reduction as the key steps. A protein-ligand X-ray crystal structure of inhibitor 3-bound HIV-1 protease (1.35 ? resolution) revealed extensive interactions in the HIV protease active site including strong hydrogen bonding interactions with the backbone. This design strategy may lead to novel inhibitors that can combat drug resistance.

Design, Synthesis, Biological Evaluation, and X-ray Studies of HIV-1 Protease Inhibitors with Modified P2′ Ligands of Darunavir

The structure-based design, synthesis, and biological evaluation of a series of nonpeptidic HIV-1 protease inhibitors with rationally designed P2′ ligands are described. The inhibitors are designed to enhance backbone binding interactions, particularly at

HIV protease inhibiting compounds

A compound of the formula is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.